Minimal residual disease in chronic lymphocytic leukemia: A consensus paper that presents the clinical impact of the presently available laboratory approaches. (4th July 2018)

• Record Type: Journal Article
• Authors: Tomuleasa, Ciprian; Selicean, Cristina; Cismas, Sonia; Jurj, Anca; Marian, Mirela; Dima, Delia; Pasca, Sergiu; Petrushev, Bobe; Moisoiu, Vlad; Micu, Wilhelm-Thomas; Vischer, Anna; Arifeen, Kanza; Selicean, Sonia; Zdrenghea, Mihnea; Bumbea, Horia; Tanase, Alina; Grewal, Ravnit; Pop, Laura; Aanei, Carmen; Berindan-Neagoe, Ioana
• Is Part Of: Critical reviews in clinical laboratory sciences. Volume 55:Number 5(2018)
• Page Start: 329
• Page End: 345
• Publication Date: 2018-07-04
• Subjects: Chronic lymphocytic leukemia -- minimal residual disease -- clinical relevance; Diagnosis, laboratory -- Periodicals; Medicine, Clinical -- Periodicals; 616.07
• DOI: 10.1080/10408363.2018.1463508
• Languages: English
• ISSNs: 1040-8363

Abstract

Abstract: Chronic lymphocytic leukemia (CLL) is a malignancy defined by the accumulation of mature lymphocytes in the lymphoid tissues, bone marrow, and blood. Therapy for CLL is guided according to the Rai and Binet staging systems. Nevertheless, state-of-the-art protocols in disease monitoring, diagnostics, and prognostics for CLL are based on the assessment of minimal residual disease (MRD). MRD is internationally considered to be the level of disease that can be detected by sensitive techniques and represents incomplete treatment and a probability of disease relapse. MRD detection has been continuously improved by the quick development of both flow cytometry and molecular biology technology, as well as by next-generation sequencing. Considering that MRD detection is moving more and more from research to clinical practice, where it can be an independent prognostic marker, in this paper, we present the methodologies by which MRD is evaluated, from translational research to clinical practice.